Adavosertib (AZD 1775 alias MK1775)–efficient in vitro in SKOV-3 and ID8 OvC cell lines, efficient in vivo in ID8 ovarian tumors in monotherapy independent on TP53 or BRCA1 status [214]. The gene discussed is BRCA1; the disease is ovarian neoplasm.